CAMBRIDGE, Mass.--(BUSINESS WIRE)--Xbiome Inc., an industry leading AI driven microbiome therapeutics company, today announced that it has acquired the clinical-stage M201 program from Assembly ...

Xbiome, an AI-driven microbiome therapeutics company, has acquired the clinical-stage M201 program from Assembly Biosciences, a clinical-stage biotechnology company developing innovative therapeutics ...

Novo Nordisk (NVO) announced Thursday it will start a late-stage clinical program next year to evaluate its new obesity therapy amycretin in subcutaneous and oral formulations. Amycretin, a ...